Multiplexed Biomarker Cartridge for Cervical Disease Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cervical cancer screening methods, including cytology and HPV nucleic acid detection, are ineffective in low-resource settings due to their subjectivity, high cost, and requirement for trained personnel and infrastructure, leading to inaccurate results and inaccessible screening for cervical disease.
Innovation Solution
A point-of-care system utilizing a multiplexed biomarker approach with a disposable cartridge conjugated with binding agents specific to HPV oncoproteins and cellular indicators, allowing for the detection of cervical disease in a biological sample, enabling self-collection and on-the-fly sample preparation, reducing the need for laboratory processing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cytology and HPV screening methods are used, then screening coverage can be achieved in resource-rich settings, but the methods require trained personnel and infrastructure that are unavailable in low-resource regions
Solution Approach 1:
The patent employs disposable cartridges containing pre-loaded reagents and binding agents for HPV and biomarker detection. These single-use cartridges eliminate the need for complex laboratory infrastructure, trained personnel for sample processing, and quality control systems, while maintaining high screening accuracy through standardized, manufacturer-optimized assay conditions.
Solution Approach 2:
The screening system enables self-collection of cervical samples by patients, with automated sample processing and result generation through the cartridge-based platform. This eliminates dependency on healthcare workers for sample collection, transport, and initial processing, making the system operational in settings without medical infrastructure.
2Measurement precision
If HPV nucleic acid detection is performed, then objective screening data is obtained, but the high worldwide incidence of HPV infections reduces specificity for actual cervical disease
Solution Approach 1:
The patent combines HPV nucleic acid detection with detection of cellular biomarkers (such as p16, Ki-67, or other cervical disease-associated proteins) in a single multiplexed assay. This integration allows differentiation between transient HPV infections and persistent infections leading to cervical intraepithelial neoplasia, thereby maintaining high sensitivity while improving specificity for clinically significant disease.
Solution Approach 2:
The screening cartridge is designed to simultaneously detect multiple targets including HPV DNA/RNA and various cellular biomarkers in a single test platform. This multi-functional approach provides comprehensive risk assessment, identifying both HPV presence and cellular changes indicative of progression to precancerous lesions.
3Reliability
If multiple screening tests are conducted to confirm cervical disease, then diagnostic accuracy is improved, but the cost and complexity of screening increases
Solution Approach 1:
The patent integrates multiple detection functions (HPV screening, biomarker detection, and sample adequacy assessment) into a single multiplexed cartridge-based platform. This consolidation maintains the diagnostic accuracy that would otherwise require sequential testing while eliminating the need for multiple separate procedures, trained personnel, and infrastructure components.
Solution Approach 2:
The universal cartridge platform performs comprehensive screening including HPV detection, cellular biomarker measurement, and internal controls for sample quality in a single standardized assay, replacing the need for multiple specialized tests and reducing overall system complexity.
4Ease of operation
If subjective cytological techniques are used for cervical screening, then disease identification can be performed, but false negative results occur due to the subjective nature of interpretation
Solution Approach 1:
The patent replaces subjective visual interpretation of cytological slides with objective, instrument-based detection of HPV nucleic acids and cellular biomarkers. The cartridge-based system generates quantifiable results through standardized chemical and biological reactions, eliminating inter-observer variability and reducing false negatives associated with subjective cytological assessment.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method provides accurate, sensitive, and specific cervical disease screening with a single procedure, reducing the need for multiple tests and expanding accessibility to cervical screening in both developed and low-resource areas.
Implementation Method 1
contacting a biological sample obtained from a patient with a plurality of binding agents specific to at least one human papillomavirus (HPV) oncoprotein
Implementation Method 2
a disposable cartridge having a chromatographic membrane formed of nitrocellulose, silica, paper, micro-patterned silicon, or polymeric materials
Data Source
AI summary
Devices and methods described herein provide improved methods of screening for cervical disease. In certain embodiments, a sample transfer and preparation vial is provided, enabling self-collection and pre-processing of cervical samples to expedite sample processing and eliminate the need for a patient to travel to a medical facility for screening. In certain embodiments, an analysis cartridge having a multiplexed biomarker panel and an immunoassay-based analyzer are provided for sample analysis. The multiplexed biomarker panel provides high sensitivity and specificity to enable effective screening with a single procedure and thus, eliminates the need for multiple tests. In certain embodiments, a method of screening for cervical disease is provided, utilizing the aforementioned multiplexed biomarker panel. The method includes detecting levels of at least two biomarkers in a cervical sample, wherein one of the biomarkers is an oncoprotein from a high-risk strain of human papilloma virus (HPV) and another is a cellular protein.